Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter, Randomized, Double-Blind, Active Controlled Trial Comparing REMICADE� (Infliximab) and REMICADE Plus Azathioprine to Azathioprine in the Treatment of Patients With Crohn's Disease Naive to Both Immunomodulators and Biologic Therapy
Brief Summary: The purpose of this study is to assess the safety and effectiveness of three different treatments for patients with Crohns disease who have not responded to previous treatment with a group of drugs commonly used to treat Crohn's Disease (5-ASA) and corticosteroids. Patients will receive either infliximab (a drug used to treat autoimmune diseases) or azathioprine (an immunosuppressant or drug used to suppress the immune system) or a combination of both for up to 34 weeks. This research study will involve approximately 500 patients. The main study involves up to 34 weeks (approximately 8 months). A study extension of an additional 20 weeks (approximately 5 months) is optional for patients who successfully complete the main study. A country-specific study extension of open label infliximab treatment for an additional 1 year is optional for patients who successfully complete the main study extension.


Options:
A: Arm Label: Mesalamin; Type: EXPERIMENTAL; Interventions: Drug: Mesalamin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Mesalamin | Intervention Type: DRUG; Name: Mesalamin; Assigned to Arm(s): Mesalamin, Placebo
B: Arm Label: Cohort 1: Induction; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Arm Label: Cohort 2: Induction; Type: EXPERIMENTAL; Interventions: Drug: BMS-936557 (Anti-IP-10 Antibody) | Arm Label: Cohort 3: Induction; Type: EXPERIMENTAL; Interventions: Drug: BMS-936557 (Anti-IP-10 Antibody) | Arm Label: Cohort 1: Maintenance; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Arm Label: Cohort 2: Maintenance; Type: EXPERIMENTAL; Interventions: Drug: BMS-936557 (Anti-IP-10 Antibody) | Arm Label: Cohort 3: Maintenance; Type: EXPERIMENTAL; Interventions: Drug: BMS-936557 (Anti-IP-10 Antibody) | Arm Label: Cohort 1: Open Label; Type: EXPERIMENTAL; Interventions: Drug: BMS-936557 (Anti-IP-10 Antibody) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1: Induction | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1: Maintenance | Intervention Type: DRUG; Name: BMS-936557 (Anti-IP-10 Antibody); Assigned to Arm(s): Cohort 2: Induction | Intervention Type: DRUG; Name: BMS-936557 (Anti-IP-10 Antibody); Assigned to Arm(s): Cohort 3: Induction | Intervention Type: DRUG; Name: BMS-936557 (Anti-IP-10 Antibody); Assigned to Arm(s): Cohort 2: Maintenance | Intervention Type: DRUG; Name: BMS-936557 (Anti-IP-10 Antibody); Assigned to Arm(s): Cohort 3: Maintenance | Intervention Type: DRUG; Name: BMS-936557 (Anti-IP-10 Antibody); Assigned to Arm(s): Cohort 1: Open Label
C: Arm Label: CDP870 400 mg; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab pegol | Intervention Type: BIOLOGICAL; Name: Certolizumab pegol; Assigned to Arm(s): CDP870 400 mg
D: Arm Label: 003; Type: EXPERIMENTAL; Interventions: Other: infliximab (IFX) infusion; azathioprine (AZA) caps | Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: infliximab (IFX) placebo infusion; azathioprine (AZA) caps | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Biological: infliximab infusion; AZA placebo caps | Intervention Type: BIOLOGICAL; Name: infliximab infusion; AZA placebo caps; Assigned to Arm(s): 002 | Intervention Type: OTHER; Name: infliximab (IFX) infusion; azathioprine (AZA) caps; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: infliximab (IFX) placebo infusion; azathioprine (AZA) caps; Assigned to Arm(s): 001

Answer: D